NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018
Richard T. Hoppe(Stanford Medicine), Ndiya Ogba(National Comprehensive Cancer Network), Joachim Yahalom(Unknown), Leo I. Gordon(Northwestern University), Robert M. Dean(Cleveland Clinic), David G. Maloney(Fred Hutch Cancer Center), Monika L. Metzger(St. Jude Children's Research Hospital), Kami J. Maddocks(The Ohio State University), Vaishalee P. Kenkre(University of Wisconsin–Madison), Jennifer L. Burns(National Comprehensive Cancer Network), Rachel Rabinovitch(University of Colorado Boulder), Ephraim P. Hochberg(Massachusetts General Hospital), Andres Forero(University of Alabama at Birmingham), Randa Tao(University of Utah), Weiyun Z. Ai(City College of San Francisco), Philippe Armand(Harvard University), Ranjana H. Advani(Stanford Medicine), David Morgan(Vanderbilt University Medical Center), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Richard F. Ambinder(Johns Hopkins University), Carolyn Mulroney(University of California San Diego Medical Center), Patricia Aoun(University of Nebraska Medical Center), Nadia Khan(Fox Chase Cancer Center), Patrick B. Johnston(Mayo Clinic in Arizona), Mark Kaminski(Sheba Medical Center), Cecil M. Benitez(Cancer Institute (WIA)), Robert Chen(AstraZeneca (United States)), Jiayi Huang(Chongqing Medical University), Joseph O. Moore(Cancer Institute (WIA)), Bouthaina S. Dabaja(The University of Texas MD Anderson Cancer Center), Philip J. Bierman(Susan Thompson Buffett Foundation), Stuart Seropian(Yale Cancer Center), Craig H. Moskowitz(University of Miami), Celeste Bello(Moffitt Cancer Center), Jane N. Winter(Northwestern University)
Cited by 63
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k